CHRS: a tool to predict risk of myeloid malignancy in CHIP/CCUS. (Top) Table of prognostic features and corresponding scores assigned in CHRS, and (bottom) cumulative incidence of hematologic malignancy among 470 960 participants in the UK Biobank stratified based on CHRS status. Top panel: From Weeks et al. Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis. New England Journal of Medicine Evidence. 2023;2(5). Copyright ©(2023) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.⁸³